Warfarin Sodium

Anticoagulant Vitamin K Antagonist

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 0.1-0.2 mg/kg q24h Duration: Variable; monitor PT/INR and adjust dose to target PT 1.5-2.5 times baseline
Notes: Start with low dose and titrate based on PT/INR. Monitor closely for bleeding.
Cat PO 0.05-0.1 mg/kg q24h Duration: Variable; monitor PT/INR and adjust dose
Notes: Cats are sensitive to warfarin; use lower doses and monitor closely.
Horse PO 0.02-0.08 mg/kg q24h Duration: Variable; monitor PT/INR
Notes: Horses may require higher doses; monitor for bleeding.
Cattle PO 0.05-0.1 mg/kg q24h Duration: Variable; monitor PT/INR
Notes: Not commonly used; use with caution.

Clinical Indications & Species Uses

General Indications
  • Anticoagulation for thromboembolic disorders
Dog (Canine)
  • Treatment and prevention of thromboembolic disease (e.g., pulmonary thromboembolism, portal vein thrombosis)
  • Adjunct in the management of immune-mediated hemolytic anemia (IMHA) to prevent thrombosis
Cat (Feline)
  • Treatment and prevention of thromboembolic disease (e.g., aortic thromboembolism)
  • Adjunct in the management of cardiomyopathy with high thromboembolic risk
Horse (Equine)
  • Treatment of thrombophlebitis
  • Prevention of thrombosis in conditions such as laminitis or sepsis

Pharmacology & Mechanism of Action

Drug Class: Anticoagulant | Pharmacological Group: Vitamin K Antagonist

Mechanism of Action: Warfarin sodium is a synthetic derivative of coumarin that acts as a vitamin K antagonist. It inhibits vitamin K epoxide reductase (VKORC1), preventing the recycling of vitamin K to its reduced form. This leads to the accumulation of inactive vitamin K-dependent clotting factors (II, VII, IX, X) and proteins C and S. The anticoagulant effect is delayed until the existing active clotting factors are depleted, typically 24-72 hours after administration. Warfarin does not affect the activity of already formed clotting factors.

Pharmacodynamics: Warfarin produces its anticoagulant effect by interfering with the hepatic synthesis of vitamin K-dependent clotting factors. The onset of action is delayed until the existing factors are cleared from circulation. The prothrombin time (PT) and international normalized ratio (INR) are used to monitor therapy. The therapeutic goal is to maintain PT/INR within a target range, usually 1.5-2.5 times baseline in dogs. Warfarin also has a narrow therapeutic index, requiring careful dose titration and monitoring.

⚑ Pharmacokinetics Summary

Absorption: Warfarin is well absorbed after oral administration, with peak plasma concentrations occurring within 1-2 hours in most species. Bioavailability is high, but food can delay absorption.
Distribution: Warfarin is extensively bound to plasma proteins, primarily albumin (approximately 99% in humans, similar in animals). It distributes into the extracellular fluid and crosses the placenta, but does not enter milk in significant amounts.
Metabolism: Warfarin is metabolized in the liver by cytochrome P450 enzymes (CYP2C9, CYP3A4, CYP1A2) to inactive metabolites. The metabolism is stereoselective, with the S-enantiomer being more potent than the R-enantiomer.
Excretion: Metabolites are excreted primarily in urine and feces. The elimination half-life is variable among species: dogs 20-45 hours, cats 20-30 hours, horses 6-8 hours, cattle 12-24 hours.
Half-Life: Dogs: 20-45 hours; Cats: 20-30 hours; Horses: 6-8 hours; Cattle: 12-24 hours
Bioavailability: High (nearly complete) after oral administration; may be reduced by food.
Protein Binding: Approximately 99% bound to plasma proteins (mainly albumin)

Available Formulations & Strengths

Oral Tablet 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg (PO)
Injectable Solution 2 mg/mL (for IV use, but not commonly used in veterinary medicine) (IV)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to warfarin or other coumarin derivatives
  • Active bleeding or hemorrhagic disorders
  • Recent surgery (especially of the central nervous system, eye, or spinal cord)
  • Severe hepatic or renal impairment
  • Pregnancy (especially first and third trimesters) and lactation (unless benefits outweigh risks)
  • Concurrent use of drugs that significantly increase bleeding risk (e.g., heparin, thrombolytics)
  • Uncontrolled hypertension
  • Bacterial endocarditis
  • Thrombocytopenia or platelet dysfunction
Warnings & Clinical Precautions:
  • Warfarin has a narrow therapeutic index; careful monitoring of PT/INR is essential.
  • Use with caution in animals with vitamin K deficiency, malnutrition, or malabsorption.
  • Avoid in animals with a history of gastrointestinal ulceration or bleeding.
  • Monitor for signs of bleeding (e.g., hematuria, melena, petechiae, prolonged bleeding from wounds).
  • Discontinue warfarin and administer vitamin K1 if severe bleeding occurs.
  • Warfarin is teratogenic; avoid in pregnant animals unless absolutely necessary.
  • Concurrent use of many drugs (e.g., NSAIDs, sulfonamides, metronidazole, cimetidine) can potentiate warfarin's effect; adjust dose accordingly.
  • In food animals, observe withdrawal times; extra-label use is prohibited in some countries.
  • Keep out of reach of children and pets; warfarin is also used as a rodenticide.

Adverse Effects & Reactions

Common:

  • Bleeding (e.g., hematuria, epistaxis, gingival bleeding)
  • Vomiting
  • Diarrhea
  • Anorexia

Serious / Severe:

  • Severe hemorrhage (e.g., intracranial, gastrointestinal, pulmonary)
  • Hemorrhagic shock
  • Death

Rare:

  • Skin necrosis
  • Purple toe syndrome
  • Hepatotoxicity
  • Hypersensitivity reactions

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
NSAIDs (e.g., aspirin, carprofen) Increased risk of gastrointestinal bleeding and potentiation of anticoagulant effect High
Sulfonamides (e.g., sulfadiazine) Displacement of warfarin from protein binding and inhibition of metabolism, increasing anticoagulant effect High
Metronidazole Inhibition of warfarin metabolism, increasing anticoagulant effect Moderate
Cimetidine Inhibition of hepatic metabolism, increasing warfarin levels Moderate
Amiodarone Inhibition of warfarin metabolism, increasing anticoagulant effect High
Vitamin K (phytonadione) Antagonizes the anticoagulant effect of warfarin High
Rifampin Induction of hepatic enzymes, decreasing warfarin effect Moderate
Phenobarbital Induction of hepatic enzymes, decreasing warfarin effect Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Hematuria
  • Melena
  • Epistaxis
  • Petechiae and ecchymoses
  • Hematemesis
  • Weakness
  • Collapse
  • Dyspnea (due to pulmonary hemorrhage)
  • Neurological signs (if intracranial hemorrhage)

Emergency Treatment Protocol: Discontinue warfarin immediately. Administer vitamin K1 (phytonadione) at a dose of 2.5-5 mg/kg SC or PO, repeated every 12 hours as needed. For severe bleeding, administer fresh frozen plasma or whole blood transfusion to replace clotting factors. Monitor PT/INR and clinical signs. Supportive care with fluids and oxygen as needed. In severe cases, consider activated charcoal if ingestion is recent.

Food Animal Withdrawal Times

πŸ₯© Meat: 30 daysπŸ₯› Milk: 7 days

Withdrawal times are not officially established for warfarin in food animals. Extra-label use is prohibited in the US for food animals. Consult regulatory authorities for specific guidance.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25Β°C, 68-77Β°F)

Light Sensitivity: Light-sensitive β€” protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in a tightly closed container. Keep out of reach of children and pets.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Warfarin is approved for human use; veterinary use is extra-label. No FDA-approved veterinary formulations exist.

Extra-Label (Off-Label) Use: In the US, extra-label use of warfarin in food animals is prohibited by the FDA due to lack of established withdrawal times and potential for residues. In companion animals, extra-label use is permitted under AMDUCA with appropriate veterinary oversight.

Clinical Pearls & Practice Notes

πŸ’‘ Clinical Insights: Warfarin is a potent anticoagulant used in veterinary medicine primarily for the treatment and prevention of thromboembolic disease. Its use requires careful patient selection, dosing, and monitoring due to its narrow therapeutic index and high risk of bleeding. The drug is most commonly used in dogs and cats, with limited use in horses. In dogs, it is often used in the management of immune-mediated hemolytic anemia (IMHA) to prevent thrombosis. In cats, it may be used for aortic thromboembolism, though newer anticoagulants like clopidogrel are often preferred. Warfarin therapy should be initiated at a low dose and titrated based on PT/INR measurements, typically targeting a PT of 1.5-2.5 times baseline. Owners must be educated on the signs of bleeding and the importance of compliance. Regular monitoring is essential, and the drug should be discontinued if severe bleeding occurs. Vitamin K1 is the antidote for warfarin overdose. Due to the availability of safer and more predictable anticoagulants, warfarin is not a first-line choice in many cases, but it remains a valuable option in certain clinical scenarios.

References & Literature

  • πŸ“š Plumb's Veterinary Drug Handbook
  • πŸ“š Papich Veterinary Pharmacology and Therapeutics
  • πŸ“š Compendium of Veterinary Products (CVP)